It is anticipated that our licensing partner will complete this final evaluation within the next six weeks, thereby enabling the commencement of sales of the new ELISA test and rapid test shortly thereafter. Whilst the Company acknowledges that there have been unfortunate delays in finalising the out-licensing arrangements in relation to our HEV diagnostic technology, these have been out of the Company’s control. Hepatitis A Additional technical and commercial progress has been made in respect of the other current major item in the SLT hepatitis product suite – our Hepatitis A rapid diagnostic test. The directors are pleased to advise that negotiations in respect of the commercialisation of the Hepatitis A rapid test have commenced. The company is confident that it will be able to conclude an attractive commercial arrangement with one or more participants in this area within the timeframe previously advised, namely around the middle of 2004, after independent evaluations of the test have been completed.
SLT Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held